InvestorsHub Logo
Followers 8
Posts 628
Boards Moderated 0
Alias Born 05/26/2021

Re: None

Tuesday, 01/11/2022 3:36:40 PM

Tuesday, January 11, 2022 3:36:40 PM

Post# of 13742
Exclusive rights :) “signed a new agreement with the MOE, which enforces exclusive rights to the Company for the use of the Rhopalurus princeps scorpion peptide and has automatically renewing terms every 10 years.”
The above is worth highlighting - having the rights till 2030 exclusively and subsequently moving forward an automatic renewal every 10 years after that… that is great!!!

2020-21 had a lot of challenges, the imunapen release to market was unfortunately delayed significantly because of packaging supplies getting stuck in China when covid presented global shipping issues .. by the end of august it went to market - woohoo. (I’m personally super happy with the products for personal use, which I’ve noted already on this board)
Here’s to a great 2022. Let’s hope this latest conference in the DR proves to bring forward and upward motion to QNTA
I’m anxious to see this stock back up over a dime again… with the right news it’ll fly IMO Even with dilution the float is very low. One winning contract and I believe we will all be Happy again :)
https://ir.quantrx.com/news-events/press-releases/detail/98/medolife-rx-presents-its-venom-to-drug-development-projects

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.